Year Founded
2015
Ownership
Private
Employees
~50
Therapeutic Areas
HematologyOncology
Stage
Phase 2
Modalities
Small molecule

7 Hills Pharma General Information

Lead candidate alintegimod completed Phase 1 showing safety and oral bioavailability. Currently in Phase 1b/2a trial testing combination with checkpoint inhibitors in PD-1 resistant tumors. Second candidate 7HP935 in IND-enabling studies.

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

alintegimod
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to 7 Hills Pharma's pipeline data

Book a demo

Key Partnerships

Texas Heart Institute, University of Texas MD Anderson Cancer Center, University of Texas Health Science Center, Icahn School of Medicine

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

7 Hills Pharma Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view 7 Hills Pharma's complete valuation and funding history, request access »

7 Hills Pharma Investors

Cancer Prevention and Research Institute of Texas
Investor Type: Venture Capital
Holding: Minority
National Cancer Institute
Investor Type: Venture Capital
Holding: Minority